In late May and July 2026, two major meta-analyses on the use of cannabidiol (CBD) for severe forms of epilepsy were published. Their findings demonstrate how far CBD research has advanced in recent years.
CBD for Drug-Resistant Epilepsy: First Meta-Analysis
The first meta-analysis combined data from 7 randomized clinical trials involving 1,154 patients with drug-resistant epilepsy. Adding CBD to standard antiseizure therapy resulted in a statistically significant reduction in seizure frequency. The most convincing results were obtained in Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex.
Cannabidiol for Severe Epileptic Encephalopathies: Second Meta-Analysis
The second, considerably broader analysis included 46 studies and 2,592 patients with severe epileptic encephalopathies. The findings were particularly notable:
- Approximately half of the patients achieved at least a 50% reduction in seizure frequency.
- More than one in four achieved a reduction of 75% or greater.
- Approximately one in seventeen became seizure-free.
CBD for Rare Genetic Forms of Epilepsy
Importantly, CBD research is gradually expanding beyond several of the best-known syndromes. Today, its use is being investigated across various epileptic encephalopathies, including rare genetic forms of the disease.
Conclusions from Cannabidiol Research in Epilepsy
These findings are no longer based on isolated successful observations. A substantial body of clinical evidence has accumulated: new studies both confirm the effectiveness of CBD in drug-resistant epilepsy and expand our understanding of the severe forms of the disease in which it may be beneficial.
Scientific References
- Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. Therapeutics and Clinical Risk Management, 2026. https://pubmed.ncbi.nlm.nih.gov/42179430/
- Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis. CNS Drugs, 2026. https://pubmed.ncbi.nlm.nih.gov/42185726/